GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetics Generation Advancement Corp (ROCO:4160) » Definitions » Other Net Income (Loss)

Genetics Generation Advancement (ROCO:4160) Other Net Income (Loss) : NT$0.0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Genetics Generation Advancement Other Net Income (Loss)?

Genetics Generation Advancement's Other Net Income (Loss) for the three months ended in Mar. 2025 was NT$0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 was NT$0.0 Mil.

Genetics Generation Advancement's quarterly Other Net Income (Loss) increased from Sep. 2024 (NT$0.0 Mil) to Dec. 2024 (NT$0.0 Mil) but then declined from Dec. 2024 (NT$0.0 Mil) to Mar. 2025 (NT$0.0 Mil).


Genetics Generation Advancement Other Net Income (Loss) Historical Data

The historical data trend for Genetics Generation Advancement's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetics Generation Advancement Other Net Income (Loss) Chart

Genetics Generation Advancement Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genetics Generation Advancement Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Genetics Generation Advancement Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetics Generation Advancement Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Genetics Generation Advancement's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetics Generation Advancement Business Description

Traded in Other Exchanges
N/A
Address
No. 28, Lane 36, Xinhu 1st Road, 6th Floor, Neihu District, Taipei, TWN, 11494
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.

Genetics Generation Advancement Headlines

No Headlines